| Trial ID: | L6498 |
| Source ID: | NCT05266261
|
| Associated Drug: |
Ibandronate Oral Tablet
|
| Title: |
Use of Ibandronate in Diabetic Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Osteoporosis, Postmenopausal|Type 2 Diabetes
|
| Interventions: |
DRUG: Ibandronate Oral Tablet
|
| Outcome Measures: |
Primary: Bone mineral density, . Percentage change in dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck, presented as least square mean and 95% confidence interval., 1 year | Secondary: Bone turnover markers, Percentage change in bone turnover markers \[Serum C-telopeptide (CTx) and procollagen type 1 N-terminal propeptide (P1NP) levels were measured by immunoassay methods using Elecsys kits - 07296355001V4 and 07296509001V4 (Roche Diagnostic Corp., Basel, Switzerland) \] presented as adjusted mean and 95% confidence interval using the generalized estimating equations for repeated measures analysis., 6 month and 12 month
|
| Sponsor/Collaborators: |
Sponsor: Yeouido St. Mary's Hospital | Collaborators: Samsung Medical Center|Seoul National University Bundang Hospital
|
| Gender: |
FEMALE
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
121
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2018-10-01
|
| Completion Date: |
2022-01-31
|
| Results First Posted: |
|
| Last Update Posted: |
2022-03-04
|
| Locations: |
Yeouido St.Mary's Hospital, Seoul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT05266261
|
